Efficacy of nebulized fluticasone propionate compared with oral prednisolone in children with an acute exacerbation of asthma  by MANJRA, A.I. et al.
Efficacy of nebulized fluticasone propionate
compared with oral prednisolone in children with
an acute exacerbation of asthma
A.I. MANJRA*, J. PRICE{, W. LENNEY{, S. HUGHES} AND H. BARNACLE}
*Westville Hospital, Westville, South Africa, {Kings College Hospital, London, {North Staffordshire Royal
Infirmary, Stoke-on-Trent and }GlaxoWellcome Research & Development, Stockley Park West, U.K.
The aim of the present study was to investigate the ecacy and safety of nebulized fluticasone propionate (FP
NebulesTM) compared with oral soluble prednisolone in children with an acute exacerbation of asthma.
The study used an international, multi-centre, randomized, double-blind, parallel group design. Three hundred
and twenty-one patients, aged 4–16 years old, who presented with an acute exacerbation of asthma, were randomly
allocated to either nebulized FP (1mg b.d.) or oral prednisolone (2mgkg71 day71 for 4 days then 1mg kg71 day71
for 3 days) for 7 days.
Patients in the FP group showed a significantly greater increase in diary card morning peak expiratory flow
(PEF) over 7 days compared with patients in the prednisolone group (difference=9?5 lmin71, CI=2?1,16?8,
P=0?034). Similar increases for both treatments were shown for evening PEF. Clinic PEF improved with both
treatments, but was significantly greater in patients taking FP after 7 days (difference=11?4 lmin71, CI=2?8, 20?0,
P=0?029). Both treatments reduced symptom scores to a similar extent. The two treatments were well tolerated,
and there was no difference in the incidence of adverse events.
The present study demonstrated that nebulized FP is at least as effective as oral prednisolone in the treatment of
children presenting with an acute exacerbation of asthma.
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Asthma is one of the most prevalent chronic diseases of
childhood, affecting approximately 10% of school-aged
children (1), and is frequently encountered in the acute care
setting. In recent years the number of hospital admissions
for acute asthma has substantially increased (2). Anti-
inflammatory therapy, particularly the use of inhaled
corticosteroids, is currently recommended by national and
international treatment guidelines as the mainstay of
preventative asthma treatment (3,4), but the role of inhaled
corticosteroids in the treatment of acute asthma is less
clearly defined.
For an acute severe asthmatic attack in children,
immediate treatment with a nebulized or inhaled b2-agonist
is recommended together with oral prednisolone
1–2mgkg71 (to a maximum 40mg) (3). Prednisolone mayReceived 27 March 2000 and accepted in revised form 17 August
2000.
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0954-6111/00/121206+09 $35?00/0reduce morbidity and the need for hospitalization in
children with acute asthma (5,6), but given daily to
children, even at low doses, has a significant adverse effect
on short-term linear growth (7) and on the hypothalamic–
pituitary–adrenal (HPA) axis (8). Although HPA axis
function rapidly returns to normal after a single short
course of prednisolone, markers of bone metabolism can
remain abnormal for several weeks (9).
High-dose inhaled corticosteroid is a potential alternative
to oral prednisolone in the treatment of acute asthma
attacks. Short courses of inhaled corticosteroids, like
beclomethasone dipropionate or budesonide, given via a
spacer, have been shown to reduce the severity of acute
asthmatic exacerbations in children (10,11).
Inhaled fluticasone propionate (FP) was introduced in
1993 as an inhaled corticosteroid with a superior ther-
apeutic ratio to those inhaled corticosteroids already in use
(12), due to its high topical activity, high anity for the
glucocorticoid receptor (13) and low oral bioavailability
(14). The ecacy and tolerability of FP has been
established in children at doses of up to 400 mg day71 for
the treatment of chronic asthma (15–20).
Recently, a nebulized formulation of FP has been
developed (21). Nebulized therapies are effective for# 2000 HARCOURT PUBLISHERS LTD
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dyspnoeic and tachypnoeic to co-ordinate inspiration using
other devices. When a child’s lung function is severely
compromised, during an acute exacerbation of asthma, it is
critical that the drug is delivered to the lung in a manner
that is not dependent on inspiratory flow or the patients’
co-ordination. In the U.K., one of the commonest routes of
administration for b2-agonists, for the initial treatment of
an acute exacerbation of asthma, is by nebulization. The
addition of a nebulized corticosteroid, instead of a systemic
one, would be more convenient, especially for ill and
distressed children, and allow more selective drug delivery
to the target organ, with less potential for systemic side-
effects.
The aim of the study was to investigate the ecacy and
safety of nebulized FP compared with oral soluble
prednisolone in children with an acute exacerbation of
asthma.
Materials and methods
STUDY DESIGN
The study was a multi-centre, randomized, double-blind,
parallel group design. Patients were treated on an inpatient
and an outpatient basis. Patients attended the clinic on the
day of presentation, after 4 (clinic visit two) and 7 days of
treatment (clinic visit three, end of treatment) and 2 weeks
after stopping treatment (follow-up visit). The study
protocol was approved by the Local or National Ethics
Committees, and conducted according to Good Clinical
Practice guidelines in accordance with the Declaration of
Helsinki 1996 (22). Each patient and/or parent/guardian
signed an informed consent form before enrolment in the
study.
RANDOMIZATION AND BLINDING
Treatment was randomized using the Glaxo Wellcome
computer programme ‘Patient Allocation for Clinical
Trials’. Each investigator was given a block, or number of
blocks, of treatments (minimum block size of four) which
were assigned in ascending order starting with the lowest
treatment number available.
Treatment packs issued to each investigator were pre-
numbered according to a block-balanced randomization
schedule. These treatment packs were labelled to ensure
that both the patient and the investigator were blinded to
treatment allocation. The active and placebo NebuleTM
containers and prednisolone tablets were identical, so that
neither the investigator nor the patients knew which
medication was received.
STUDY POPULATION
Patients were eligible to take part in the study if they met
the following criteria at screening: were aged 4–16 years
inclusive, and had an established diagnosis of asthma; wereable to use a mini-Wright peak flow meter and a metered
dose inhaler (MDI); had a parent/guardian willing to give
informed consent; presented with an acute exacerbation.
An acute exacerbation of asthma was defined as a peak
expiratory flow (PEF) of 40–75% predicted, with a clinical
scoring index of 2 at presentation to clinic or other acute
care setting.
TREATMENT
Three hundred and twenty-one patients were enrolled into
the study and randomly assigned to one of the following
treatment groups for 7 days:
. FP NebulesTM 1mg b.d. (260?5mg 2ml71 b.d.) and
placebo soluble tablets once daily.
. Placebo NebulesTM twice daily (260?9% saline
2ml71 b.d.) and soluble prednisolone tablets once
daily [2mg kg71day71 (maximum of 40mg day71) for
4 days; 1mgkg71 day71 (maximum of 20mg day71)
or half the original dose for 3 days].
Patients nebulized the contents of two NebulesTM (4ml)
to dryness twice daily (morning and evening). Tablets (5mg
per tablet) were taken once daily in the morning. The
number of tablets to be taken each day was calculated in the
same way for each patient, irrespective of their treatment
allocation (i.e. 2mgkg71 day71 rounded up to the nearest
10 up to a maximum of 40mg). After 4 days the calculation
was repeated to give half the dose. Salbutamol, via MDI or
NebulesTM was provided for relief of symptoms on an ‘as
required’ basis.
PRIMARY EFFICACY VARIABLES
The primary ecacy variables were morning and
evening PEF measured by patients, and recorded on daily
record cards (DRC). Bronchodilator therapy was withheld,
where possible, for 4 h before recording PEF. Patients
recorded the best of three PEF measurements, using a
mini-Wright peak flow meter on waking in the morning and
in the evening (at bedtime), before taking any study
medication.
SECONDARY EFFICACY VARIABLES
Secondary ecacy variables included patient derived data
(symptoms), clinic assessment of pulmonary function,
clinical scoring index and patient/parent and investigator
global evaluation.
The symptoms of cough, sputum production, wheeze and
dyspnoea were recorded morning and evening on patient
DRCs. In the morning symptoms were scored from 0 (no
symptoms during the night) to 4 (symptoms so severe did
not sleep at all). When going to bed symptoms were scored
from 0 (no symptoms during the day) to 5 (symptoms so
severe could not perform normal daily activities).
The clinical scoring index was assessed at each clinic visit.
The score assigned represented the sum of the score for
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dependent on age), wheezing (0=none to 3=severe),
inspiration/expiration ratio (0=2:1 to 3=1:3) and acces-
sory muscle use (0=none to 3=marked use). After 7 days
of treatment, and at the follow-up visit both patient/parent
and the investigator rated the benefit of the study
medication from 1 (very beneficial) to 4 (worse). Pulmonary
function was also assessed at each clinic visit. Patients were
instructed to withhold inhaled b2-agonist therapy for at
least 4 h, and the highest of three PEF measurements were
recorded. Forced expiratory volume in 1 sec (FEV1), forced
vital capacity (FVC) and mid-expiratory flow (FEF25–75%)
were assessed on an optional basis.
PATIENT COMPLIANCE
Questions in the case report form and information on the
daily record card were used to establish correct use of study
medication. Reasons for non-compliance were recorded.
The number of NebulesTM/tablets returned were recorded
in the drug dispensing logs. Drug accountability was
checked regularly at monitoring visits.
SAFETY EVALUATIONS
Safety assessments included withdrawal from the study,
adverse event monitoring and HPA axis function assessed
by morning serum cortisol concentrations.
Withdrawal and adverse event monitoring
Patients had the right to withdraw from the study at any
time. Patients could also be withdrawn from the study by
an investigator if it was considered detrimental to the
patients’ health to continue. An adverse event was defined
as any untoward medical occurrence experienced by a
patient, whether or not it was caused by the study drug.
Adverse events were rated by the investigator as serious or
non-serious, and the cause assessed as either unrelated,
unlikely, possibly, probably or almost certainly related to
the drug. All adverse events and reasons for withdrawal
were documented.TABLE 1. Characteristics of patients at baseline
Patient characteristics
Sex
Age (years)
Height (cm)
Weight (kg)
No. of patients taking corticosteroids at randomization
Results are expressed at the mean+SD.Serum cortisol concentrations
Blood samples were taken at the start of treatment and on
day 7 (ideally between 08?00 and 10?00 hours). Whole blood
(4ml) was drawn into a lithium–heparin collection tube.
The contents were mixed thoroughly and centrifuged at
1500 g for 10min at 48C within 2–3 h of collection. Plasma
was separated, transferred to polypropylene sample tubes,
frozen and stored at 7208C until analysis. Serum samples
were assayed for cortisol by an immunoassay method.
STATISTICAL ANALYSES
All analyses were performed using SAS software (version
6?08). Treatment differences were assessed using two-sided
90% confidence intervals. Treatment groups were deemed
equivalent if the 90% confidence intervals for treatment
differences in mean morning and evening PEF were within
+15 lmin71. Assuming a maximum standard deviation of
50 lmin71, a total of 380 evaluable patients (190 per
treatment group) were required to ensure a power of 80%.
Analysis of covariance was used to analyse diary card
and clinic visit lung function (mean morning and evening
PEF, clinic visit PEF, FEV1, FVC and FEF25–75%) with
terms for baseline, treatment, age, sex, country and type of
nebulizer included in the model. Differences between the
two treatment groups with respect to symptom scores, use
of relief medication, clinical scoring index and global
evaluation were analysed using the Van Elteren extension
to the Wilcoxon rank sum test, using country as the
stratifying variable. Confidence limits were calculated using
an unstratified Wilcoxon rank sum test.
Results
In total, 321 patients (mean age 9 years) were randomized
to treatment (165 to the FP group and 156 to the
prednisolone group). There was no significant difference
in baseline characteristics between the two treatment
groups (Table 1). The majority of patients (99%) had a
history of asthma between 1 and 10 years, and had not been
hospitalized in the previous 12 months, although 75% had
experienced at least one episode of emergency care in the
previous 12 months. Severity of exacerbations with respectFluticasone propionate
(n=165)
Prednisolone
(n=156)
92male/73 female 89male/67 female
9?0+3?0 8?0+2?8
134?0+16?5 132?0+16?8
31?0+12?0 32?0+13?5
4 (2%) 3 (2%)
TABLE 2. Effect of nebulized fluticasone propionate (1 b.d.) and oral prednisolone (2mg kg71 day71 for 4 days then
1mgkg71 day71 for 3 days) for 7 days on clinic measured PEF, FEV1, FVC and FEF25–75% in children suffering from an
acute exacerbation of asthma
Lung function FP day 1 FP day 7 Pred day 1 Pred day 7
PEF (lmin71) 179+75 264+83 170+72 248+85
(n=165) (n=159) (n=156) (n=150)
Adjusted mean PEF (SE) day 7 263?3+4?0* 251?9+4?3
FEV1 (l) 1?34+0?63 1?65+0?60 1?35+0?49 1?72+0?59
(n=48) (n=54) (n=46) (n=46)
FVC (l) 1?65+0?76 1?92+0?68 1?73+0?64 2?16+0?74
(n=49) (n=53) (n=44) (n=44)
FEF25–75% 1?31+0?72 1?78+0?85 1?35+0?66 1?81+0?74
(l sec71) (n=44) (n=46) (n=40) (n=37)
Results are expressed as the mean+SD unless otherwise stated.
*P=0?029 vs. prednisolone day 7.
Abbreviations: FP: fluticasone propionate; Pred.: prednisolone; PEF: peak expiratory flow; SE: standard error; FEV1: forced
expiratory volume in 1 sec; FVC: forced vital capacity; FEF25–75%: mid-expiratory flow.
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1 were well matched between treatment groups (Table 2).
PRIMARY EFFICACY VARIABLES
Mean morning and evening PEF (measured by patients on
DRC) increased over the 7-day treatment period in both
treatment groups (Fig. 1). Mean morning PEF (+SD)
increased from 178+68 to 255+88 lmin71 in the FP group
and from 183+70 to 227+84 lmin71 in the prednisolone
group. The mean morning PEF for the first day was based
on relatively fewer patients as many started their treatment
in the middle of the day. Similarly, mean evening PEF
(+SD) increased from 198+81 to 236+82 lmin71 in the FP
group, and from 186+85 to 244+86 lmin71 in the
prednisolone group. Patients treated with FP had a greater
increase from baseline in mean morning PEF of 77 lmin71,
compared with 44 lmin71 for patients treated with pre-
dnisolone (difference=9?5 lmin71, CI=2?1, 16?8,
P=0?034), and had a mean increase in evening PEF of
65 lmin71 compared with 58 lmin71 for patients treated
with prednisolone. The two treatments were equivalent with
respect to evening PEF, with 90% confidence limits within
+15 lmin71 (difference=3?8 lmin71, CI=73?3, 10?9;
P=0?375). No patients were excluded form the ecacy
population due to poor compliance.
SECONDARY EFFICACY VARIABLES
Both FP and prednisolone reduced the following symptom
scores over the 7-day treatment period: cough, sputum
production, wheeze, dyspnoea, bronchodilator use, number
of times awoken during the night due to asthma as well as
clinical scoring index and parental/guardian and investi-
gator global evaluation [Table 3(a) and (b)]. Investigators
and parents/guardians judged both treatments to be‘beneficial’ or ‘very beneficial’ in the treatment of asthmatic
children. There were no differences in symptom scores
between treatments.
Clinic PEF improved with both treatments (Table 2). By
day 7 patients taking FP had a significantly greater
improvement in PEF compared with patients taking
prednisolone (difference=11?4 lmin71, CI=2?8, 20?0,
P=0?029). Patients treated with FP had a mean increase
in PEF of 84 lmin71 by day 7 compared with 78 lmin71 for
patients in the prednisolone group. FP and prednisolone
treatment were equivalent at day 4 (difference=3?8 lmin71,
CI=74?4, 12?1, P=0?443).
Clinic FEV1, FVC and FEF25–75% also improved with
both treatments (Table 2). Patients treated with FP had a
mean increase in FEV1, FVC and FEF25–75% of 0?35 l,
0?35 l and 0?48 l sec71 respectively. Similarly, patients
treated with prednisolone had a mean increase in FEV1,
FVC and FEF25–75% of 0?37 l, 0?45 l and 0?4 l sec
71
respectively. No difference between treatments was found.
SAFETY MEASURES
Withdrawals and adverse events
The distribution of withdrawals was similar in both the FP
and prednisolone treatment groups. In total 11 patients
withdrew after randomization, six patients (4%) from the
FP group and five patients (3%) from the prednisolone
group. Of the six patients who withdrew from FP
treatment, four patients withdrew due to an adverse event.
One patient withdrew due to failure to comply with the
protocol, and one patient withdrew due to concerns about
taking corticosteroids. Of the five patients who withdrew
from prednisolone treatment, three patients withdrew due
to an adverse event. One patient withdrew due to lack of
ecacy, and one patient withdrew at the parent’s request.
Fig. 1. Effect of nebulized fluticasone propionate (1mg b.d.) and oral predinisolone (2mg kg71day71 for 4 days then 1mg
kg71day71 for 3 days) for 7 days on dairy card mean morning and evening peak expiratory flow 1min71). Results are
expressed as the mean + SE. ^: fluticasone propionate; ~: prednisolone.
TABLE 3. Effect of nebulized fluticasone propionate (1mg b.d.) and oral prednisolone (2mg kg71day71 for 4 days then
1mgkg71 day71 for 3 days) for 7 days on (a) daytime and (b) night-time symptom-scores in children suffering from an acute
exacerbation of asthma
(a)
Symptoms FP day 1 FP day 2 Pred. day 1 Pred. day 2
Cough score 3?0 (0?075?0) 1?0 (0?073?0) 3?0 (0?075?0) 1?0 (0?073?0)
(n=141) (n=99) (n=131) (n=89)
Sputum production score 1?0 (0?075?0) 0?0 (0?073?0) 1?0 (0?075?0) 0?0 (0?073?0)
(n=139) (n=98) (n=129) (n=89)
Wheeze score 2?0 (0?075?0) 0?0 (0?074?0) 2?0 (0?075?0) 0?0 (0?072?0)
(n=142) (n=99) (n=130) (n=89)
Dyspnoea score 1?0 (0?075?0) 0?0 (0?074?0) 1?0 (0?075?0) 0?0 (0?073?0)
(n=138) (n=98) (n=128) (n=88)
No. times Ventolin used (day and night) 2?0 (0?071?00) 0?0 (0?077?0) 2?0 (0?0715?0) 0?0 (0?078?0)
(n=140) (n=142) (n=130) (n=138)
(b)
Cough score 2?0 (074?0) 0?0 (0?073?0) 1?0 (0?074?0) 0?0 (0?074?0)
(n=54) (n=145) (n=49) (n=141)
Sputum production score 1?0 (0?074?0) 0?0 (0?073?0) 1?0 (0?073?0) 0?0 (0?073?0)
(n=52) (n=143) (n=48) (n=141)
Wheeze score 2?0 (0?075?0) 0?0 (0?074?0) 1?0 (0?073?0) 0?0 (0?073?0)
(n=54) (n=144) (n=47) (n=140)
Dyspnoea score 2?0 (0?075?0) 0?0 (0?074?0) 1?0 (0?074?0) 0?0 (0?073?0)
(n=53) (n=142) (n=47) (n=138)
Results are presented as median (range).
Abbreviations: FP: fluticasone propionate; Pred.: prednisolone. 0=no symptoms during the day; 1=symptoms for one short
period during the day; 2=symptoms for two or more short periods during the day; 3=symptoms for most of the day which
did not affect normal daily activities; 4=symptoms for most of the day which did affect normal daily activities; 5=symptoms
so severe could not go to school or perform normal daily activities.
Results are presented as median (range).
Abbreviations: FP: fluticasone propionate; Pred.: prednisolone. 0=no symptoms during the night; 1=symptoms caused you
to wake once or wake early; 2=symptoms caused you to wake twice or more (including waking early); 3=symptoms caused
you to be awake for most of the night; 4=symptoms so severe that you did not sleep at all.
1210 A. I. MANJRA ET AL.
FLUTICASONE PROPIONATE VERSUS PREDNISOLONE IN THE TREATMENT OF ACUTE ASTHMA 1211The incidence of adverse events was also similar in both
the FP and prednisolone treatment groups. Adverse events
were reported in 57 patients (35%) taking FP and 44
patients (28%) taking prednisolone. Of those patients 30
(18%) had an FP-related adverse event and 24 patients
(15%) had a prednisolone-related adverse event. The most
common drug-related adverse events were candidiasis of the
mouth/throat [FP, 14 (8%); prednisolone, five (3%)],
nausea and vomiting [FP, seven (4%); prednisolone, eight
(5%)], asthma [FP, six (4%); prednisolone, six (4%)],
candidiasis of an unspecified site [FP, five (3%); predniso-
lone, four (3%)], temperature regulation disturbances [FP,
four (2%); prednisolone, four (3%)] and cough [predniso-
lone, four (3%)]. Three patients (2%) in the FP group and
one patient (51%) in the prednisolone group experienced a
serious adverse event which was related to an exacerbation
of asthma. These serious adverse events were not drug-
related.
Serum cortisol concentrations
A small proportion of patients produced a valid blood
sample (between 08?00 and 10?00 hours) at the start and
end of treatment for determination of morning serum
cortisol concentrations: 14 patients on day 1 and 49 patients
on day 7 for the FP group; 17 patients on day 1 and 57
patients on day 7 in the prednisolone group. More patients
produced a valid blood sample on day 7 as the time of
blood sampling was not dependent on the time of their
exacerbation. The mean serum cortisol concentrations for
the FP group remained unchanged from 223 nmol l71 at the
start of treatment (n=14) to 228 nmol l71 at day 7 (n=49)
(ratio of change from day 1 to day 7=0?93). When all
samples were included in the analysis, mean serum cortisol
concentrations in the FP group fell from 205 nmol l71
(n=150) to 177 nmol l71 (n=148) from start of treatment
to day 7 (ratio of change=0?84). The assay for serum
cortisol cross-reacted with prednisolone, so data in that
group were invalidated and could not be compared with
serum cortisol concentrations in the FP group.
Discussion
The present study showed that, in children with an acute
exacerbation of asthma, mean morning and evening PEF
and clinic-measured PEF increased over the 7-day treat-
ment period in both treatment groups. However, patients in
the nebulized FP group experienced a greater increase in
both morning and clinic-measured PEF than patients in the
prednisolone group. Both treatments were effective in
reducing asthma symptom scores and were well tolerated.
Assuming a maximum standard deviation of 50 lmin71,
a total of 380 evaluable patients (190 per treatment groups),
were required to ensure a power of 80%. In total, 321
patients were randomized to treatment, meaning that the
trial may have been slightly under-powered. However, the
actual standard deviation for PEF calculated was39 lmin71 which was less than originally anticipated, and
so the anticipated power of 80% was achieved.
Although the role of inhaled FP in controlling symptoms
in asthmatic children is well established (16,17,19, 20, 23), it
is less clearly defined for acute exacerbations. Francis et al.
showed that nebulized FP (1mg b.d.) was as effective as
oral prednisolone (once daily) in the treatment of pre-
school children with an acute exacerbation of asthma (24).
In addition, when given by MDI and spacer device FP
increased mean morning, evening and clinic-measured PEF
to a greater extent compared with oral prednisolone in 143
children aged 4–16 years who presented to clinic with an
acute exacerbation of asthma (25). In these studies and in
the present study, oral prednisolone was given once daily.
Although there is evidence to support the fact that twice
daily dosing with nebulized budesonide is more effective
than once daily dosing in the treatment of stable asthma
(26), no such studies have been published in acute asthma
for either FP or prednisolone. Therefore, we are unable to
comment on what contribution the difference in adminis-
tration regimen influenced our observations.
Large doses of other corticosteroids like beclomethasone
dipropionate (10) or budesonide (11) given via a spacer also
reduced the severity of acute episodic asthma in children. In
a prospective study, Volovitz et al. (8) showed that inhaled
budesonide (via Turbuhaler1) was at least as effective as
oral prednisolone at controlling moderately severe acute
asthma attacks in children. Unlike prednisolone, treatment
with budesonide did not suppress serum cortisol concentra-
tions and produced an earlier clinical response.
The results of the present study are in agreement with a
previous study in adults. Levy et al. showed that oral
prednisolone and high dose inhaled FP (2mg b.d.) given by
MDI and large volume spacer were effective in the
treatment of asthma exacerbations (27). Treatment failures,
defined as a reduction in PEF of 60%, were similar in both
groups (23% prednisolone group; 27% FP group) and 48%
of patients were defined as a treatment success in both
groups. However, this study was carried out in adults with
mild exacerbations which did not require admission to
hospital.
Several studies have investigated the effectiveness of
nebulized corticosteroids in children with an acute exacer-
bation of asthma. Curtis et al. showed that there was no
difference between nebulized budesonide (1mg b.d.) and
oral prednisolone (2mg kg71 day71) in terms of PEF and
FEV1 after 24 h in children with an acute exacerbation of
asthma (28). However, when salmeterol was co-adminis-
tered with nebulized budesonide, oxygen saturation,
respiratory rate, pulmonary index and respiratory distress
score were significantly improved compared with patients
who received oral prednisolone and salbutamol. In addi-
tion, the proportion of patients who were fit for discharge
after 2 h was significantly higher in the budesonide group
(29). Scarfone et al. compared nebulized dexamethasone
(1?5mgkg71) with oral prednisolone (2mgkg71 day71) in
111 asthmatic children with a moderately severe acute
exacerbation of asthma, and showed that there was no
difference in the rate of admissions to hospital between the
two groups (30). However, clinical improvement occurred
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nebulized corticosteroid. Increased peripheral deposition of
nebulized drug to the lungs compared with MDI or dry
powder inhaler (31), coupled with independence from
patient’s inspiratory flow and co-ordination may account
for the beneficial clinical effects observed in children with
an acute exacerbation of asthma.
In the present study, the immunoassay method used to
analyse the serum cortisol cross-reacted with prednisolone
to a substantial extent. The historical laboratory estimate of
cross-reactivity was 33%, but this was clearly much
higher in the blood samples from the prednisolone group in
this study. Therefore, it was not possible to compare the
serum cortisol concentrations in the prednisolone group
with those of the FP group. However, the adjusted mean
serum cortisol concentration (measured between 08?00 and
10?00 hours) for patients taking FP did not change over the
7 days of treatment, highlighting the good safety profile of
FP. When the analysis included all samples, patients taking
FP had some reduction in mean serum cortisol concentra-
tion after 7 days of treatment, but the magnitude of change
was small (ratio of change 0?84) and was not associated
with any significant clinical effects. However, this study was
not adequately powered for within group comparisons.
A complication in the measurement of morning serum
cortisol concentrations in the present study was the fact
that patients were recruited to the study at various times of
the day, since their first visit was dependent on their
exacerbation. Therefore, the time at which the first blood
sample was taken varied and was only taken between 08?00
and 10?00 hours (as required for a valid determination of
morning serum cortisol concentration) in 14 patients in the
FP group and 17 patients in the prednisolone group. In
addition, patients were not required by the protocol to
withhold the morning dose of prednisolone at the end of
treatment when blood samples were taken.
A further study, with the identical treatments and study
duration (FLTB3055) (32) was specifically designed and
carried out to address the sampling problems and cross-
reactivity encountered in the present study, in order to
provide appropriate safety data to support the present
study. Twenty-four hour urinary cortisol concentrations
were measured using a more sensitive reverse phase high
pressure liquid chromatography assay to avoid problems of
cross-reactivity with prednisolone observed in the present
study. Nebulized FP (1mg b.d.) reduced 24-h urinary
cortisol concentrations to below the lower limit of detection
in 29% of children (eight patients) with stable asthma,
compared with 86% of children (25 patients) in the
prednisolone group. Treatment with nebulized FP reduced
24-h urinary cortisol concentrations from 14?4 ngml71 to
9?3 ngml71, which was significantly less than in the
prednisolone group (12?8 ngml71 to 5?2 ngml71)
(P=0?001) (32).
Inhaled corticosteroids are known to have fewer systemic
side-effects compared with oral or parenteral corticoster-
oids (33). Inhaled FP administered via large volume spacer,
did not suppress HPA axis function, measured by 24-h
urinary-free cortisol excretion, in children with stable
asthma after 4 days of treatment (15). Similarly, high-doseinhaled budesonide (1600mg day71) for 2 days, followed by
a 25% decrease in dose every second day for a further 7
days did not suppress serum cortisol concentrations in
children with recurrent wheezing episodes at the start of
treatment during exacerbations of their asthma. In these
children, high dose inhaled budesonide was just as effective
as oral prednisolone (2mgkg71 day71 for 2 days followed
by a decrease in dose every second day for a further 7 days)
(34).
In the present study, the incidence of total and drug-
related adverse events was similar in both groups, with oral
candidiasis being the most commonly reported (8% of
patients in the FP group compared with 3% of patients in
the prednisolone group). No previous studies with FP in
children experiencing an acute asthma exacerbation have
reported the incidence of oral candidiasis, but in a study by
Westbroek et al. 14% of adult patients with chronic asthma
taking nebulized FP (1mgday71) developed oral candidia-
sis (21). In addition, a review by Hughes indicates the
incidence of oral candidiasis in subjects taking inhaled FP
from 0% to 31%, which is no different from the incidence
with other inhaled corticosteroids (35).
The results of the present study show that nebulized FP
(1mg b.d.) is at least as effective as oral prednisolone for the
treatment of acute exacerbations of asthma in children.
Both FP and prednisolone increased PEF, but patients
taking FP had a significantly higher morning and clinic-
measured PEF than patients taking prednisolone. Both
treatments were well tolerated and there was no difference
in the incidence of adverse events during this short-term
treatment. Systemic effects of nebulized FP are likely to be
less than with oral corticosteroids, and was confirmed by a
supportive study comparing these two treatments in terms
of their effects on 24-h urinary cortisol excretion in children
with asthma.
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